All News
Ab#1582 @RheumNow #ACR23
RA-ILD outcomes of TNFi v non-TNF b/tsDMARD
VA Data, propens match emulation study
No incr risk of death in TNFi vs non-TNFi
But are TNF safe?
- Don't support systematic avoidance. But are there specific pops - unsure. Don't answer if efficacy in RA-ILD https://t.co/AApEjZs4DM
Eric Dein ( View Tweet)
Important plenary session, RA-ILD outcomes in VA cohort study
No difference in death/hospitalization for TNF vs non-TNF treated patients. Jives w/my priors; I do NOT avoid TNF in RA-ILD
Encouraging if you (like me) prefer RA-active tx for RA-ILD 😉😆
@RheumNow #ACR23 #ACRBest https://t.co/TIDzMLOfs4
Mike Putman EBRheum ( View Tweet)
World's largest jSSc cohort: djSSc pts had more severe dz vs ljSSc pts. DjSSc pts w/ more cutaneous, vascular, MSK involvement vs ljSSc pts w/ more cardiac involvement. No significant differences in ILD, PAH, GI involvement. #ACR23 Abs #1623 https://t.co/czAH0hpY2a @rheumnow https://t.co/RcfAJORXY3
Dr. Rachel Tate ( View Tweet)
Non TNFi b/tsDMARDs vs TNFi in RA-ILD. New-User, Propensity Score Matched Study. 454 patients. No difference! resp-related hospitalisation aHR 1.22 [0.92, 1.60] No difference mortality. Abstr#1582 #ACR23 #ACRbest @RheumNow https://t.co/HzzVo9dJHi https://t.co/mZuHq4GShU
Richard Conway ( View Tweet)
The SMART study by Dhir et al: once-weekly, oral split-dose MTX (10mg/15mg) in RA pts had⬆️efficacy & ⬇️need for addtl DMARDs vs. once-weekly, single-dose MTX
Reassuring.
. . .
In my practice, pts tolerate MTX split dosing better esp w/⬆️doses
#ACR23 ABST1583 @RheumNow https://t.co/F8p2aKmmH4
sheila ( View Tweet)
#ACR23 Abs #1032 identified six major themes of diverse patient experiences. Studying patient experiences is critical for understanding mechanisms of health disparity, targeting interventions and, ultimately, improving quality of care. https://t.co/Fd2m4yzlHp @rheumnow https://t.co/EhIIF9cquQ
Dr. Rachel Tate ( View Tweet)
RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Long term follow up T2T in RA
12 yrs BeST & 20yrs IMPROVED studies
50% recalled
68% remission 91% LDA
HAQ 0.5
These are GOOD outcomes
Especially considering setup before we had several MoAs
What’s lacking: current ttmt & number of bioD, ctrl group
@RheumNow ABST1273 #ACR23 https://t.co/9KcsHLupJc
Aurelie Najm ( View Tweet)
#ACR23 Abstr#1579 More data on the role of SGLT2-i in #SLE. Data from EHR using propensity match scoring showed the use of SGLT2-i vs DPP4-i (for nonSLE indication) was associated with reduced risk of MACE (HR:0.69)and poor renal outcomes inc. ESRD (HR:0.71) @RheumNow https://t.co/7k0o3m18AN
Md Yuzaiful Md Yusof ( View Tweet)
Does NSAID use = CKD?
Large Korean study on CKD in ankylosing spondylitis pts showed risk of CKD associated with comorbidities.
Long term NSAID use not associated with increased risk of CKD.
@RheumNow #ACR23 Abs#1394 https://t.co/m3kYI30gBc
Robert B Chao, MD ( View Tweet)
OA and Microbiome!
Ab#1581 @RheumNow #ACR23
Microbiome transplantation of mouse models - benefit if before or soon after OA induction (meniscal destabilization)
⭐️OA is inflammatory dis of innate immune sys, not "wear-and-tear" and gut biome may be a 🔑 https://t.co/eA8unUBnpC
Eric Dein ( View Tweet)
Risk of CKD in AS patients was associated with comorbidities, not NSAID use. #ACR23 Abs #1394 https://t.co/cbOPvjOCyq @rheumnow https://t.co/O0rhbMFiOX
Dr. Rachel Tate ( View Tweet)
Majority of pts with axSpA had below avg aerobic capacity indicating high risk of morbidity.
Importance of supporting pts with axSpA to lead healthy lifestyle and improved aerobic capacity by exercise!
@RheumNow #ACR23 Abs#1395 https://t.co/SFAStGQaK0
Robert B Chao, MD ( View Tweet)
Apremilast associated with improvement in LDL, obesity and diabetic A1c in PsA pts, especially in those with worse levels at baseline!
Can consider apremilast use in PsA with high burden of comorbid cardiometabolic diseases
@RheumNow #ACR23 Abs#1414 https://t.co/fL9UWcaZgG
Robert B Chao, MD ( View Tweet)
RA-ILD is an heterogeneous condition
Different risk factors identified dep/ on radiographic pattern
RA-UIP:
-male sex OR 2.7
-ACPA+ OR 2.2
-male + ACPA + smoking OR 13
RA-NSIP:
-RF+ OR 3.2
Likely to support different pathological mechanisms
@RheumNow #ACR23 ABST1269 https://t.co/rC2F9YAceQ
Aurelie Najm ( View Tweet)
Can US differentiate pain? In #ACR23 Abs. #1388 PsA pts who have pain & inflammatory enthesitis on US, process pain differently than the US negative patients, despite the induction of pain or discomfort on all groups. Interesting finding. https://t.co/YcccLoQCBj @rheumnow https://t.co/o94bMwndxX
Dr. Rachel Tate ( View Tweet)
Finally meeting @synovialjoints after 3 years of reporting together for @RheumNow!
Some serious interviews on AxSPA going on at the booth, I won’t reveal who was his guest: you’ll have to find out on https://t.co/YxAt6H2Qza https://t.co/dQHPw3pS3d
Aurelie Najm ( View Tweet)
What if you have a first degree relative with ankylosing spondylitis?
100 pts w/o previous rheum dx w/ 1st degree AS relative
17% had MRI sacroiliitis
25% met classification criteria
14% dx with AS
@RheumNow #ACR23 Abs#1403 https://t.co/Z0juhRnLki
Robert B Chao, MD ( View Tweet)
15-year results from Abs #1389 at #ACR23 found only low back pain to be predictor of spinal radiographic progression in axSpA pts. Mean and median progression changes by mSASSS per year less in this cohort than previously documented. https://t.co/VKTEZWvH7f @rheumnow https://t.co/6sjPrcw2dD
Dr. Rachel Tate ( View Tweet)
Biologics are working for ankylosing spondylitis, even in reducing cardiovascular mortality!
Large retrospective study of over 4k pts over 20 years showed decrease in CV mortality from 34% in 1999 to 21% in 2020
@RheumNow #ACR23 Abs#1399
#ACRbest https://t.co/wKCIXHza0v
Robert B Chao, MD ( View Tweet)